$SSTI

SoundThinking Q2 Earnings Call Highlights

SoundThinking (NASDAQ:SSTI) said Q2 delays in professional-services work and slower SafePointe deployments reduced its 2026 revenue outlook by about $2 million and shifted some work into 2027. It also removed a nearly $1.5 million Puerto Rico ShotSpotter recapture from 2026 guidance and cut full-year adjusted EBITDA margin to 8% to 9%. ShotSpotter bookings and go-lives lagged, while renewals totaled over $23 million and a Texas TAG CrimeTracer deal adds about $2.5 million in annual recurring rev

Original reporting
Published Aug 14, 2026, 3:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 3:48 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SoundThinking Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$SSTIBearishMed
01

Why it matters

The most market-relevant items are the quantified 2026 revenue reduction, the adjusted EBITDA margin guidance cut to 8% to 9%, and the explanation that booked projects are shifting into 2027 rather than being lost. Offsetting positives include strong renewal activity, ARR growth expectations, and a new multi-year CrimeTracer contract valued at about $2.5M in annual recurring revenue.

02

Market read

Traders should focus on the guidance reset (revenue and EBITDA margin) and the stated revenue recognition timing tied to go-lives, while monitoring whether renewal strength and ARR growth can offset near-term revenue pressure.

03

What to watch

The guidance cut is tied to specific deployment and project timing, so the market may need to separate temporary go-live delays from longer-term customer adoption or sales-cycle deterioration.

Relevance 7/10Novelty 6/10Timing: during/after Q2 earnings call, pre-market today

Background

The piece summarizes SoundThinking’s Q2 earnings call, focusing on guidance changes, SafePointe and ShotSpotter execution, CrimeTracer contract wins, and balance sheet/outlook details.

Company-level read

Ticker impact

$SSTIBearishMedium confidence
Context

SoundThinking cut 2026 revenue by about $2M and reduced full-year adjusted EBITDA margin guidance to 8% to 9% due to SafePointe deployment delays and project shifts into 2027.

Expected impact

Near-term downside bias versus prior expectations, with volatility driven by whether investors focus on revenue timing versus resilient ARR/renewals.

Evidence & confidence

The article provides specific guidance reductions (revenue and EBITDA margin) and explains drivers (deployment delays, professional-services delays, contract recapture removal), which typically pressure near-term valuation even if ARR and renewals are strong.

Market effects

Public-safety tech demand appears resilient on renewals/ARR, but deployment go-lives and government funding timing can materially delay revenue recognition.

US municipal and state procurement cycles (including post-hurricane and federal funding wind-down) are highlighted as a swing factor for near-term bookings-to-revenue conversion.

Limited, aside from a canceled South Africa tender due to political developments, which is not quantified beyond the cancellation mention.

Counterpoint

Investors may underreact because ARR is still expected to rise above $100M entering 2027 and the company reported over $23M in multi-year renewals, suggesting demand strength despite timing issues.

Key entities

  • SoundThinking

    NASDAQ-listed public safety technology provider; reported Q2 call highlights including guidance reductions and contract/renewal updates.

  • SafePointe

    Acoustic/related deployment system referenced as having longer-than-anticipated deployments affecting 2026 revenue timing.

  • ShotSpotter

    Gunshot detection system described as underperforming on bookings and go-lives, with elongating sales cycles and funding headwinds.

  • CrimeTracer

    Law enforcement search engine; received a new multi-year Texas Anti-Gang Program contract and additional statewide deals.

Related articles

$ARAIMed

Arrive AI (ARAI) Q2 2026 Earnings Call Transcript

Arrive AI (ARAI) held its Q2 2026 earnings call. Management reported revenue of $14.7 million, a net loss of $14.1 million, and non-GAAP net loss of $4.3 million. Cash and liquid investments were $5.1 million at June 30, with about $1.1 million monthly burn. The company outlined AP3 Plus shipments, a 2027 ramp, and financing capacity via an S-3 and $15 million ATM.

$RMTIMedAI 8/10

Rockwell Medical (RMTI) Q2 2026 Earnings Call Transcript

Rockwell Medical (RMTI) reported Q2 2026 net sales of $17.8 million, up 11% year over year, with gross profit $3.2 million and gross margin expanding to 18%. Net loss improved to $1.2 million, and operating cash flow turned positive at $2.1 million. FY 2026 guidance: revenue $70 million to $75 million, gross margin 18% to 22%, and adjusted EBITDA $1 million to $2 million. The company completed a 1-for-10 reverse split for Nasdaq bid-price compliance.

$SPRYMed

ARS Pharmaceuticals Q2 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) said it expanded its field sales force and will target high-value prescribers, noting neffy has about 8% market share in the field-targeted universe versus ~1% in non-targeted. Commercial coverage is 90%. Q2 operating expenses were $95.1M. ARS expects cash-flow breakeven by end-2027 and Phase IIb CSU interim data in Q1 2027.

$STNEMed

StoneCo Q2 Earnings Call Highlights

StoneCo (NASDAQ: STNE) reported Q2 results on an earnings call. Adjusted net income fell slightly YoY, but adjusted EPS rose 9% on a lower share count from repurchases. For 1H, it posted BRL 3.1B adjusted gross profit and BRL 4.58 adjusted basic EPS, and kept 2026 guidance. Management cited higher-for-longer Selic rates, retention efforts, Pix growth, and rising credit costs.

$QSIMed

Quantum-Si Q2 Earnings Call Highlights

Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.